CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President. Mr. Wilson brings nearly 20 years of legal, compliance and executive experience and accomplishment within the life sciences industry. Mr. Wilson will be responsible for the Legal and Compliance functions and serve as a key member of the leadership team.
“The Rocket family is thrilled to welcome Martin to our talented executive leadership team as we advance our world-class pipeline of gene therapies and unlock cures for patients facing devastating rare disease,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. “Martin’s vast legal and compliance expertise, coupled with exceptional leadership experiences at life science companies of varying sizes, scales our existing capabilities as we rapidly expand in support of our ambition to seek gene therapy cures.”
Prior to joining Rocket, Mr. Wilson was General Counsel and Chief Corporate Officer at Ichnos Sciences, where he oversaw Legal, Compliance, Business Development, Human Resources and IT. Mr. Wilson helped establish Ichnos as an independent corporate entity and set up its corporate structure. Before Ichnos, Mr. Wilson served as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources at Teligent, Inc. Prior to Teligent, he was Vice President and Assistant General Counsel at Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals. Mr. Wilson held multiple roles of increasing responsibility at Par over the course of 11 years, including Chief Compliance Officer.
“Rocket’s dynamic culture, long-term vision and unyielding devotion to patients drew me to this opportunity,” said Mr. Wilson. “I’m excited to work with the Rocket leadership team and contribute to the company’s success as it advances first-in-class gene therapies for rare, devastating diseases.”
Earlier in his career, Mr. Wilson held a role in the Licensing group at Schering-Plough. He earned his Juris Doctorate from Villanova University Charles Widger School of Law.
About Rocket Pharmaceuticals Leadership
The Rocket leadership team is comprised of seasoned industry veterans with rich and extensive experience in drug development and approvals across public and private pharmaceutical and biotechnology companies of various sizes. Leadership team members have led the development and approval of numerous gene therapy and rare disease drugs on the market for previously unmet medical needs and have served in significant roles within the U.S. Food and Drug Administration (FDA). Uniquely, Rocket’s multi-platform gene therapy approach necessitates the leadership of two Chief Development Officers, one specializing in lentiviral vector (LVV)-based gene therapy and a second specializing in adeno-associated virus (AAV)-based gene therapy.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.
